Showing 2951-2960 of 4087 results for "".
- Incyte Reports Positive Vitiligo Phase 3 Data Supporting JAK Therapieshttps://practicaldermatology.com/news/incyte-reports-positive-vitiligo-phase-3-data-supporting-jak-pipeline/2486888/Incyte provided updated data on two therapies in its dermatology pipeline during its recent earnings call, according to a statement from the company. Ruxolitinib Update
- TYK2-JAK1 Inhibitor Treatment Promising for Individuals with Refractory Dermatomyositishttps://practicaldermatology.com/news/tyk2-jak1-inhibitor-treatment-promising-for-individuals-with-refractory-dermatomyositis/2486481/Results from the Phase 3 VALOR trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting revealed that individuals with re
- Study: Mycophenolate Mofetil Effective as First-Line Option for Juvenile Localized Sclerodermahttps://practicaldermatology.com/news/study-mycophenolate-mofetil-effective-as-first-line-option-for-juvenile-localized-scleroderma/2485505/A new study comparing methotrexate (MTX) and mycophenolate mofetil (MMF) suggests MMF may offer a comparable alternative with better patient-reported tolerability outcomes. Researchers analyzed data from 114 patients (MTX [n=68
- NICE Recommends First Topical JAK Inhibitor for CHE in England and Waleshttps://practicaldermatology.com/news/nice-recommends-first-topical-jak-inhibitor-for-che-in-england-and-wales/2484333/The National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Anzupgo® (delgocitinib) cream for adult patients with moderate to severe chronic hand eczema (CHE) who have not responded to,
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://practicaldermatology.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients
- Analysis: Higher Infection and Acne Risks with JAK Inhibitors in ADhttps://practicaldermatology.com/news/analysis-higher-infection-and-acne-risks-jak-inhibitors-ad/2468381/Researchers for a new analysis have provided a data and analytics framework for the evaluation of the safety of immune-modulating drugs (IMDs) in treating atopic dermatitis (AD). The study authors designed the system to generate timely, high-quality evidence using sequential propensity sco
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At